Cogent Biosciences, Inc. Net Income Loss

• Cogent Biosciences, Inc. showed a decrease of -28.6% in Net Income Loss from 2024 to 2025.
• This data is from Cogent Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Cogent Biosciences, Inc.'s Net Income Loss has declined by 1,190.4%.
• Historical annual values: Fiscal year 2025: -$328.94 million | Fiscal year 2024: -$255.86 million | Fiscal year 2023: -$192.41 million | Fiscal year 2022: -$140.24 million | Fiscal year 2021: -$72.27 million | Fiscal year 2020: -$74.81 million | Fiscal year 2019: -$31.83 million | Fiscal year 2018: -$34.53 million | Fiscal year 2017: -$25.49 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026